This chapter focuses on the development of drugs targeting the N-terminal domain of
nuclear hormone receptors, using progress with the androgen receptor as an example …

Tumor heterogeneity strongly affects the molecular mechanisms driving resistance to
hormonal therapies in castration-resistant prostate cancer. Since the current use of available …

Polycystic ovary syndrome (PCOS) affects 8‑13% of reproductive‑age females worldwide
and mutations or aberrant expression of androgen receptor (AR) may cause the onset of this …

Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (<
0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a …

Background As compared to endocrine responsive breast cancer bone is less frequent site
of distant recurrence in triple-negative breast cancer (TNBC). A biomarker which predicts …

Bladder cancer (BlCa) exhibits a gender disparity where men are three times more likely to
develop the malignancy than women suggesting a role for the androgen receptor (AR). Here …

Androgen receptor splicing variant 7 (AR-V7) is a truncated variant of the AR mRNA that
may be a predictive biomarker for AR-targeted therapy. AR-V7 has been described in …

Nearly 20 different transcripts of the human androgen receptor (AR) are reported with two
currently listed as Refseq isoforms in the NCBI database. Isoform 1 encodes wild-type AR …

Testosterone and 5α–dihydrotestosterone acting through the androgen receptor (AR) direct
virilization of the male fetus during embryogenesis, and the development of primary and …

Androgen receptor (AR) belongs to the steroid hormone receptor group of ligand-activated
transcription factors in the nuclear receptor superfamily. AR mediates the action of …